Photodynamic therapy and anti-tumour immunity.

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45

Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44

Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc (2008) 2.21

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89

Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res (2009) 1.80

Photodynamic therapy for localized infections--state of the art. Photodiagnosis Photodyn Ther (2009) 1.73

Light-induced cell damage in live-cell super-resolution microscopy. Sci Rep (2015) 1.72

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol (2007) 1.64

Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol (2009) 1.62

Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res (2007) 1.55

Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) (2011) 1.45

Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.39

Photodynamic therapy for treatment of solid tumors--potential and technical challenges. Technol Cancer Res Treat (2008) 1.36

The role of photodynamic therapy (PDT) physics. Med Phys (2008) 1.32

High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model. Lasers Surg Med (2007) 1.26

Deep penetration of a PDT drug into tumors by noncovalent drug-gold nanoparticle conjugates. J Am Chem Soc (2011) 1.24

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A (2008) 1.23

Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. Exp Cell Res (2008) 1.19

CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer (2007) 1.14

Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics. Theranostics (2013) 1.12

Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 1.12

Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11

Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11

Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A (2014) 1.10

Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int J Radiat Oncol Biol Phys (2010) 1.09

Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol (2012) 1.08

Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine (Lond) (2011) 1.07

Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res (2010) 1.07

A graphene quantum dot photodynamic therapy agent with high singlet oxygen generation. Nat Commun (2014) 1.04

Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin. Br J Cancer (2006) 1.03

Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy. ChemMedChem (2008) 1.02

Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release (2009) 1.02

Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci (2011) 1.00

Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci (2012) 0.99

Shedding light on nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.97

Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PLoS One (2011) 0.96

Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells. Int J Cancer (2009) 0.95

Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors. Coord Chem Rev (2008) 0.94

Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Mol Pharm (2011) 0.94

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer (2011) 0.94

Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia. J Control Release (2011) 0.93

Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res (2013) 0.93

DNA "nano-claw": logic-based autonomous cancer targeting and therapy. J Am Chem Soc (2014) 0.92

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br J Cancer (2007) 0.92

Programmable and multiparameter DNA-based logic platform for cancer recognition and targeted therapy. J Am Chem Soc (2014) 0.91

Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J (2010) 0.91

Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils. Photochem Photobiol (2011) 0.90

The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci (2015) 0.90

Nanoscopic micelle delivery improves the photophysical properties and efficacy of photodynamic therapy of protoporphyrin IX. J Control Release (2011) 0.89

Vascular targeting to the SST2 receptor improves the therapeutic response to near-IR two-photon activated PDT for deep-tissue cancer treatment. Biochim Biophys Acta (2013) 0.89

Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One (2013) 0.89

Stem cells loaded with nanoparticles as a drug carrier for in vivo breast cancer therapy. Adv Mater (2014) 0.89

Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies. PLoS One (2012) 0.89

5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer (2014) 0.89

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev (2015) 0.89

A core-shell-shell nanoplatform upconverting near-infrared light at 808 nm for luminescence imaging and photodynamic therapy of cancer. Sci Rep (2015) 0.89

Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer (2013) 0.88

Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases. Cell Death Dis (2013) 0.88

Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc (2013) 0.88

Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine. J Med Chem (2014) 0.88

Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. Nat Commun (2014) 0.88

Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects. World J Immunol (2014) 0.87

Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel. PLoS One (2009) 0.87

Label-Free, Longitudinal Visualization of PDT Response In Vitro with Optical Coherence Tomography. Isr J Chem (2012) 0.87

Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87

Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia. Cell Stress Chaperones (2014) 0.87

Melanoma resistance to photodynamic therapy: new insights. Biol Chem (2013) 0.86

Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response. Int J Oncol (2010) 0.86

Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitization. Biochem Biophys Res Commun (2011) 0.86

Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation. PLoS One (2012) 0.86

Immunotherapy for bladder cancer. Res Rep Urol (2015) 0.86

A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics (2014) 0.86

The immunosuppressive side of PDT. Photochem Photobiol Sci (2011) 0.86

Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget (2015) 0.86

Heat shock protein 70 is acute phase reactant: response elicited by tumor treatment with photodynamic therapy. Cell Stress Chaperones (2010) 0.85

Regulated necrosis in HeLa cells induced by ZnPc photodynamic treatment: a new nuclear morphology. Int J Mol Sci (2014) 0.85

Combination of photodynamic therapy and immunomodulation: current status and future trends. Med Res Rev (2008) 0.85

Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84

Confocal fluorescence imaging enables noninvasive quantitative assessment of host cell populations in vivo following photodynamic therapy. Theranostics (2012) 0.84

Optical Imaging, Photodynamic Therapy and Optically Triggered Combination Treatments. Cancer J (2015) 0.84

Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.84

Photofrin based photodynamic therapy and miR-99a transfection inhibited FGFR3 and PI3K/Akt signaling mechanisms to control growth of human glioblastoma In vitro and in vivo. PLoS One (2013) 0.83

CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J Biophotonics (2013) 0.83

Rapid upregulation of cytoprotective nitric oxide in breast tumor cells subjected to a photodynamic therapy-like oxidative challenge. Photochem Photobiol (2011) 0.83

Triggered Nanoparticles as Therapeutics. Nano Today (2013) 0.83

Superoxide mediates direct current electric field-induced directional migration of glioma cells through the activation of AKT and ERK. PLoS One (2013) 0.83

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. Br J Cancer (2011) 0.82

InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett (2015) 0.82

Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget (2016) 0.82

Immunophototherapy using PDT combined with rapid intratumoral dendritic cell injection. Photochem Photobiol (2008) 0.82

Photodynamic therapy induces an immune response against a bacterial pathogen. Expert Rev Clin Immunol (2012) 0.82

Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. Int J Cancer (2015) 0.81

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun (2016) 0.81

The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review. Neurosurg Rev (2016) 0.81

Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Res (2015) 0.81

The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naive recipients. Photochem Photobiol (2008) 0.81

Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr Biol (Camb) (2013) 0.81

Pheophorbide a-Mediated Photodynamic Therapy Triggers HLA Class I-Restricted Antigen Presentation in Human Hepatocellular Carcinoma. Transl Oncol (2010) 0.81

Drug Carrier for Photodynamic Cancer Therapy. Int J Mol Sci (2015) 0.80

BODIPY-doped silica nanoparticles with reduced dye leakage and enhanced singlet oxygen generation. Sci Rep (2015) 0.80

Dendritic cells and the control of immunity. Nature (1998) 56.54

Toll-like receptors. Annu Rev Immunol (2001) 26.06

Function and activation of NF-kappa B in the immune system. Annu Rev Immunol (1994) 17.04

MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol (1979) 15.58

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04

Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06

Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60

Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18

Coley's toxins in perspective. Nature (1992) 3.40

Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34

The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci (2002) 3.23

TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant (2004) 3.15

The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol (2002) 3.09

The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol (1990) 2.08

Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad Sci (2005) 2.03

Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem (2004) 2.02

Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol (2001) 1.90

Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res (2004) 1.80

Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72

An outline of the hundred-year history of PDT. Anticancer Res (2003) 1.70

Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res (2006) 1.64

Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol (1999) 1.60

Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des (2002) 1.59

Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther (2005) 1.52

Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer (2003) 1.52

Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res (2005) 1.49

TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol (2004) 1.45

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother (2004) 1.44

Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res (1997) 1.42

Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res (2002) 1.39

Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther (2005) 1.39

Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol (2002) 1.35

The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res (1996) 1.35

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 1.32

Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg (1996) 1.31

Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization. Cancer Res (1991) 1.30

Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer (1995) 1.29

Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol (2004) 1.29

Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res (1996) 1.28

Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res (1996) 1.28

Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B (2000) 1.27

Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26

Immune response against dying tumor cells. Adv Immunol (2004) 1.26

Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res (1990) 1.25

Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene (2006) 1.24

Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol (1986) 1.22

Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. Cancer Res (1995) 1.22

Vascular effects of photodynamic therapy. Anticancer Res (2002) 1.21

Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res (1999) 1.19

Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer (2004) 1.19

Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med (Berl) (1999) 1.19

Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett (2002) 1.15

Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res (2002) 1.14

Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem (2003) 1.14

NF-kappa B: arresting a major culprit in cancer. Drug Discov Today (2002) 1.13

Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res (1989) 1.12

Thoracotomy is associated with significantly more profound suppression in lymphocytes and natural killer cells than video-assisted thoracic surgery following major lung resections for cancer. J Invest Surg (2005) 1.12

Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem Photobiol Sci (2002) 1.10

Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res (2004) 1.09

Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst (1990) 1.09

Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res (1996) 1.09

Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol (2004) 1.08

Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev (2003) 1.07

Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer (1997) 1.06

Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res (2002) 1.05

Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res (1997) 1.05

Photodynamic therapy and the immune system in experimental oncology. Photochem Photobiol Sci (2002) 1.03

Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother (2005) 1.03

Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res (2000) 1.01

Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci (2004) 1.01

Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. Anticancer Drugs (1994) 1.01

Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood (2000) 0.99

Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg (2005) 0.99

Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol (1994) 0.99

Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res (2003) 0.98

A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Br J Cancer (2006) 0.97

Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr Pharm Des (2005) 0.97

Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol (2001) 0.97

Effect of irradiation fluence rate on the efficacy of photodynamic therapy and tumor oxygenation in meta-tetra (hydroxyphenyl) chlorin (mTHPC)-sensitized HT29 xenografts in nude mice. Radiat Res (2002) 0.97

Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol (2003) 0.97

Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer (2000) 0.96

The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology (2003) 0.96

T cell immunity induced by live, necrotic, and apoptotic tumor cells. J Immunol (2004) 0.95

Immunomodulatory aspects of photodynamic therapy. Expert Opin Investig Drugs (1998) 0.95

Detection of photodynamic therapy-induced early apoptosis in human salivary gland tumor cells in vitro and in a mouse tumor model. Oral Oncol (2004) 0.95

Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res (2003) 0.95

Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol (2003) 0.94

Nuclear factor kappa B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem Photobiol (1993) 0.93

Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J Photochem Photobiol B (1998) 0.92

Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). Cancer Lett (1994) 0.92

BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol (2002) 0.92

Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. Urology (1989) 0.91

Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer (2002) 0.91

Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J Photochem Photobiol B (1991) 0.91

Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol (1999) 0.90

Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem Photobiol (2005) 0.90

Induction of Hsp60 by Photofrin-mediated photodynamic therapy. J Photochem Photobiol B (2001) 0.90

Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08

Biphasic dose response in low level light therapy. Dose Response (2009) 2.78

The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng (2011) 2.37

Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med (2004) 2.12

Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother (2005) 1.89

Role of low-level laser therapy in neurorehabilitation. PM R (2010) 1.79

Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One (2011) 1.76

Photodynamic therapy for localized infections--state of the art. Photodiagnosis Photodyn Ther (2009) 1.73

Biphasic dose response in low level light therapy - an update. Dose Response (2011) 1.69

Protease-stable polycationic photosensitizer conjugates between polyethyleneimine and chlorin(e6) for broad-spectrum antimicrobial photoinactivation. Antimicrob Agents Chemother (2006) 1.58

Targeted photodynamic therapy of established soft-tissue infections in mice. Photochem Photobiol Sci (2004) 1.57

Use of chitosan bandage to prevent fatal infections developing from highly contaminated wounds in mice. Biomaterials (2006) 1.51

Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother (2009) 1.50

Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. J Photochem Photobiol B (2005) 1.50

Light-emitting diode therapy (LEDT) before matches prevents increase in creatine kinase with a light dose response in volleyball players. Lasers Med Sci (2015) 1.46

Antimicrobial effects of photodynamic therapy on patients with necrotic pulps and periapical lesion. J Endod (2007) 1.46

Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) (2011) 1.45

Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med (2010) 1.45

Can surgical site infections be treated by photodynamic therapy? Photodiagnosis Photodyn Ther (2010) 1.43

Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resist Updat (2012) 1.42

Photodynamic therapy for infections: clinical applications. Lasers Surg Med (2011) 1.42

Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed Laser Surg (2010) 1.38

Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radic Biol Med (2007) 1.37

Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. Lasers Surg Med (2007) 1.36

Low-level light stimulates excisional wound healing in mice. Lasers Surg Med (2007) 1.36

Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct (2009) 1.35

Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg (2013) 1.34

Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection. Lasers Surg Med (2007) 1.33

Photodynamic therapy with fullerenes. Photochem Photobiol Sci (2007) 1.32

Effects of growth phase and extracellular slime on photodynamic inactivation of gram-positive pathogenic bacteria. Antimicrob Agents Chemother (2004) 1.31

Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice. Photochem Photobiol Sci (2005) 1.29

Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol (2005) 1.28

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A (2008) 1.23

Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Rev Anti Infect Ther (2011) 1.23

Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother (2006) 1.22

Effect of pulsing in low-level light therapy. Lasers Surg Med (2010) 1.21

Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. PLoS One (2011) 1.21

Shock wave-mediated molecular delivery into cells. Biochim Biophys Acta (2002) 1.19

Helicobacter pylori in patients can be killed by visible light. Lasers Surg Med (2005) 1.15

Comparison of therapeutic effects between pulsed and continuous wave 810-nm wavelength laser irradiation for traumatic brain injury in mice. PLoS One (2011) 1.15

Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. Lasers Surg Med (2012) 1.15

Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res (2009) 1.14

Antimicrobial strategies centered around reactive oxygen species--bactericidal antibiotics, photodynamic therapy, and beyond. FEMS Microbiol Rev (2013) 1.13

Photodynamic inactivation of Acinetobacter baumannii using phenothiazinium dyes: in vitro and in vivo studies. Lasers Surg Med (2010) 1.12

Human platelet-rich plasma- and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo. PLoS One (2012) 1.12

Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 1.12

Effect of chitosan acetate bandage on wound healing in infected and noninfected wounds in mice. Wound Repair Regen (2008) 1.11

Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11

Type I and Type II mechanisms of antimicrobial photodynamic therapy: an in vitro study on gram-negative and gram-positive bacteria. Lasers Surg Med (2012) 1.11

Antimicrobial photodynamic inactivation and photodynamic therapy for infections. Methods Mol Biol (2010) 1.11

Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J Immunol (2006) 1.11

Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers. Antimicrob Agents Chemother (2010) 1.10

Transcranial low-level laser therapy improves neurological performance in traumatic brain injury in mice: effect of treatment repetition regimen. PLoS One (2013) 1.10

Photochemical activation of TRPA1 channels in neurons and animals. Nat Chem Biol (2013) 1.09

Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother (2008) 1.09

Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections. Nanomedicine (Lond) (2010) 1.09

Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med (2013) 1.08

Chitosan acetate bandage as a topical antimicrobial dressing for infected burns. Antimicrob Agents Chemother (2008) 1.07

Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice. Antimicrob Agents Chemother (2011) 1.07

Animal models of external traumatic wound infections. Virulence (2011) 1.07

Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine (Lond) (2011) 1.07

Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert Rev Anti Infect Ther (2012) 1.07

Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother (2012) 1.07

Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol (2012) 1.07

Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics Lasers Med (2012) 1.07

Dose response effects of 810 nm laser light on mouse primary cortical neurons. Lasers Surg Med (2011) 1.06

Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. J Neurotrauma (2014) 1.05

Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother (2007) 1.05

All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease. Virulence (2011) 1.05

Low-level laser therapy (808 nm) reduces inflammatory response and oxidative stress in rat tibialis anterior muscle after cryolesion. Lasers Surg Med (2012) 1.05

Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem (2002) 1.04

Photodynamic inactivation of Bacillus spores, mediated by phenothiazinium dyes. Appl Environ Microbiol (2005) 1.02

Blue light eliminates community-acquired methicillin-resistant Staphylococcus aureus in infected mouse skin abrasions. Photomed Laser Surg (2013) 1.02

Light based anti-infectives: ultraviolet C irradiation, photodynamic therapy, blue light, and beyond. Curr Opin Pharmacol (2013) 1.02

Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J (2013) 1.01

Paradoxical potentiation of methylene blue-mediated antimicrobial photodynamic inactivation by sodium azide: role of ambient oxygen and azide radicals. Free Radic Biol Med (2012) 1.00

Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease. Photomed Laser Surg (2011) 1.00

Involvement of skeletal muscle gene regulatory network in susceptibility to wound infection following trauma. PLoS One (2007) 1.00

Innovative cationic fullerenes as broad-spectrum light-activated antimicrobials. Nanomedicine (2009) 1.00

Treatment of Helicobacter pylori infection with intra-gastric violet light phototherapy: a pilot clinical trial. Lasers Surg Med (2009) 1.00

Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro. J Biophotonics (2012) 0.99

Imidazole metalloporphyrins as photosensitizers for photodynamic therapy: role of molecular charge, central metal and hydroxyl radical production. Cancer Lett (2009) 0.99

Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care (2012) 0.98

In vitro photodynamic therapy and quantitative structure-activity relationship studies with stable synthetic near-infrared-absorbing bacteriochlorin photosensitizers. J Med Chem (2010) 0.98

Low level laser therapy increases angiogenesis in a model of ischemic skin flap in rats mediated by VEGF, HIF-1α and MMP-2. J Photochem Photobiol B (2013) 0.98

Introduction to experimental and clinical studies using low-level laser (light) therapy (LLLT). Lasers Surg Med (2010) 0.97

Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol (2014) 0.97

Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol (2010) 0.97

Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care (2012) 0.95

Synthesis and characterization of highly photoresponsive fullerenyl dyads with a close chromophore antenna-C(60) contact and effective photodynamic potential. J Mater Chem (2010) 0.95

Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J Antimicrob Chemother (2011) 0.95

Effect of red and near-infrared wavelengths on low-level laser (light) therapy-induced healing of partial-thickness dermal abrasion in mice. Lasers Med Sci (2013) 0.95

Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrob Agents Chemother (2011) 0.94

Ultraviolet-C light for treatment of Candida albicans burn infection in mice. Photochem Photobiol (2011) 0.94

Far infrared radiation (FIR): its biological effects and medical applications. Photonics Lasers Med (2012) 0.94